Side Area Logo
Welcome to unde omnis iste natus error sit voluptatem accusantium
Keep conected
Overview(2)

INVESTORS

Press Releases

Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates

WARRINGTON, Pa., Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a conference call and webcast (including a slide presentation) at 8:00 AM EST on Thursday, February 16, 2017 to provide updates on the AEROSURF phase 2 clinical program, the recently announced closing of a $10.5 million private offering and other business and development activities.

To participate in the live call and take part in the question and answer session, dial (844) 802-2436 (domestic) or (412) 317-5129 (international). The live webcast, including a slide presentation, can be accessed at http://windtreetx.investorroom.com/events.

A replay of the conference call will be accessible one hour after completion by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing passcode 10101774. An archive of the webcast can be accessed on the Company's website at http://windtreetx.investorroom.com/events.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.

For more information, please visit the Company's website at www.windtreetx.com.

SOURCE Windtree Therapeutics, Inc.

For further information: John Tattory, Senior Vice President and Chief Financial Officer: 215.488.9418 or jtattory@windtreetx.com

print email rss